Beta Drugs- Standalone HY2-FY21 Net profit rises to Rs. 3.91 crore against Rs. 3.09 crore in HY2-FY20
Beta Drugs – Standalone HY2-FY21 Revenue reached Rs.44.97 crore against Rs. 31.38 crore in HY2-FY20.
Company : Beta Drugs Limited
Beta Drugs announced its Standalone and consolidated financial results for the half year and period ended on 31st March, 2021.
Financials for Standalone HY2 at Beta Drugs in FY20-21 are as follows:- Revenue reached Rs.44.97 crore while previous year corresponding period it was Rs. 31.38 crore. - Net profit rises to Rs. 3.91 crore against Rs. 3.09 crore in a year ago period. - Earning per share was Rs. 4.07against Rs. 3.26 in a year ago period.
Standalone annual revenue in FY20-21 reached Rs. 80.06 crore against Rs.65.73 crore with net profit of Rs. 6.97 crore against Rs. 7.09 crore. Earning per share was Rs.7.26 against Rs. 7.49 at Beta Drugs.
Following are the consolidated HY2 financials at Beta Drugs in FY20-21:- Revenue reached Rs. 64.98 crore whereas previous year corresponding period it was Rs. 44.40 crore - PAT rises to Rs. 6.54 crore against Rs. 4.29 crore in a year ago period. - EPS was Rs. 6.81 while preceding year same period it was profit of Rs. 4.53 per share.
Consolidated annual revenue at Beta Drugs in FY20-21 reached Rs.116.61 crore against Rs. 91.21 crore with Net profit of Rs.11.72 crore against Rs. 9.41 crore and Earning per share was Rs. 12.20 against Rs.9.93.